Clinical commercialization is imminent, but revenue remains lumpy and management provides no 2026 guidance.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-04-02 |
| Length | 55 minutes |
| EPS | $-0.05 |
| EPS consensus | $-0.04 |
| Revenue | $985076.00 |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q2 FY25 · Q1 FY25
All VNRX earnings · Back to VNRX overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.